论文部分内容阅读
[目的]探讨非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)突变状态及其与临床病理特征的关系。[方法]收集符合入组条件的NSCLC患者300例,应用RT-PCR方法检测EGFR突变,采集临床常见的19、21外显子突变位点(delE746-A750、delL747-P753insS、L858R、L861Q)信息,分析EGFR突变状态与临床病理特征的关系。[结果]300例NSCLC患者中,EGFR突变72例,突变率24%;其中男、女性突变率分别为13.06%和45.54%(P<0.01);吸烟与非吸烟者突变率分别为10.69%和34.31%(P<0.01);腺癌与非腺癌突变率分别为30.72%和15.67%(P=0.02)。[结论]EGFR突变是NSCLC特殊类型,与女性、非吸烟、腺癌人群密切相关。
[Objective] To investigate the relationship between epidermal growth factor receptor (EGFR) mutation and clinicopathological features in patients with non-small cell lung cancer (NSCLC). [Methods] A total of 300 NSCLC patients were enrolled in this study. EGFR mutations were detected by RT-PCR and the common 19, 21 exon mutation sites (delE746-A750, delL747-P753insS, L858R, L861Q) , Analyze the relationship between EGFR mutation status and clinicopathological features. [Results] Among 300 patients with NSCLC, 72 patients had EGFR mutation with a mutation rate of 24%. The mutation rates of male and female were 13.06% and 45.54%, respectively (P <0.01). The mutation rates of smoking and non-smoking were 10.69% and 34.31% (P <0.01). The mutation rates of adenocarcinoma and non-adenocarcinoma were 30.72% and 15.67% respectively (P = 0.02). [Conclusion] EGFR mutation is a special type of NSCLC, which is closely related to female, non-smoking and adenocarcinoma populations.